Sort By:

Genetics Propels DIAN Toward Therapies

CONFERENCE COVERAGE 2019-08-02 Conference Coverage Each year, the DIAD family conference held in advance of the Alzheimer's Association International Conference features a science update, and this year the focus was on genetics. DIAN families know that the modern era of Alzheimer ...

Expression, Expression, Expression—Time to Get on Board with eQTLs

CONFERENCE COVERAGE 2019-04-19 Conference Coverage Next-generation genetic analysis has opened the floodgates to a wave of new gene discovery. Whole-exome and-genome sequencing have nearly doubled the number of previously known Alzheimer’s genes (see Part 1 of this story). But modern ...

Crenezumab Update: Baseline Data from Colombian Prevention Trial

CONFERENCE COVERAGE 2019-08-08 Conference Coverage A subset of the world’s largest known kindred of autosomal-dominant Alzheimer’s disease, near the Colombian city of Medellin, have enrolled in the Banner Alzheimer Prevention Initiative Autosomal Dominant Alzheimer’s Disease trial. It ...

Paper Alert: MS4A Variants May Sway Alzheimer’s Risk Via TREM2

RESEARCH NEWS 2019-08-15 Research News Variants in the MS4A gene cluster influence AD risk, at least in part, by tweaking levels of another AD risk factor, TREM2. In a study published in Science Translational Medicine on August 14, researchers co-led by Bruno Benitez, Celeste ...

Why Bother With Round Robins on Blood Tests? Q&A with Kaj Blennow

CONFERENCE COVERAGE 2019-08-21 Conference Coverage At the AAIC conference held July 14–18 in Los Angeles, Kaj Blennow of the University of Gothenburg had his hands full trying to get researchers in the field engaged in the nitpicky drudgery of validation, standardization, and ...

Nixing Complement Protein Protects Neurons in Tauopathy Model

RESEARCH NEWS 2019-08-25 Research News Complement proteins may be helpful when it comes to rallying clearance of hazardous debris from the brain, but scientists believe the immune activators can also inflict irreparable damage to neurons and their synapses. A paper published ...

Refining Models of Amyloid Accumulation in Alzheimer’s Disease

CONFERENCE COVERAGE 2016-08-29 Conference Coverage The knowledge that Alzheimer’s disease begins with a preclinical phase that lasts for 20 years or more has focused researchers’ minds on prevention. However, they need to know more about how fast pathology progresses, how to predict ...

Raw Deal: Lose Ataxin, Gain BACE

RESEARCH NEWS 2019-08-29 Research News CAG trinucleotide repeat expansions in the ataxin-1 gene cause spinocerebellar ataxia type 1, a fatal neurodegenerative disease. Curiously, variants of this same gene, sans trinucleotide repeat expansions, associate with risk for Alzheimer’s ...

Technology Brings Dementia Detection to the Home

CONFERENCE COVERAGE 2019-08-30 Conference Coverage The past decade has seen increasing use of technology in dementia research. Computer games that provide cognitive training have become part of prevention studies, and trialists are working to move cognitive testing out of the clinic ...

Smart Homes Open Doors to Insights into Aging, Dementia

CONFERENCE COVERAGE 2019-08-30 Conference Coverage Replicating existing paper-and-pencil tests on tablets or smartphones is one thing (Part 13 of this series), but what about taking technology itself to the next level? What are the prospects for continuously collecting information on ...

Colombian Cohort Delivers Data on Blood NfL

CONFERENCE COVERAGE 2019-08-08 Conference Coverage At the Alzheimer’s Association International Conference, held July 14–18 in Los Angeles, a blood test indicating that neurons in the brain are degenerating generated considerable buzz. Eric Reiman, Banner Alzheimer’s Institute, Phoenix ...

NGF Gene Therapy Trial Data Published

RESEARCH NEWS 2018-03-29 Research News Two years ago, investigators announced mixed results of a small, Phase 2 trial of a gene therapy aimed at nurturing the survival of at-risk cholinergic neurons in people with AD. While brain injections of CERE-110, an adeno-associated virus ...

Results of Ladostigil Trial Published

RESEARCH NEWS 2019-09-13 Research News In a second Phase 2 strikeout, the small-molecule drug ladostigil missed its primary endpoint of curbing progression from mild cognitive impairment to AD, though people on a low-dose regimen did have less brain shrinkage over three years ...

Current Filters

  • TYPE: News x

Remove all filters

Filter By

  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From